Enjaymo (sutimlimab) rapidly stopped hemolysis — destruction of red blood cells — while anti-cancer treatment targeted the underlying blood…
Articles by Margarida Maia, PhD
A 55-year-old man with severe lung disease and cold agglutinin disease (CAD) successfully underwent a lung transplant with no…
Combining a complement inhibitor with rituximab was found to rapidly control severe autoimmune hemolytic anemia (AIHA), including in two…
Careful planning, warming measures, and close teamwork between medical specialists may allow for the safe collection and transplant of blood-forming…
Rituximab plus glucocorticoids led to sustained disease remission in an older woman who developed cold agglutinin disease (CAD)…
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to Ouro Medicines’ experimental treatment gamgertamig for autoimmune…
A short course of rituximab, combined with chemotherapy agents and corticosteroids, can keep primary cold agglutinin disease (CAD)…
Enjaymo (sutimlimab-jome) remains safe to use over the long term, according to new real-world data from adults with primary…
A woman with hard-to-treat cold agglutinin disease (CAD) was later found to have high-grade gastric B-cell lymphoma — a…
A U.S. man in his 60s developed cold agglutinin disease (CAD) as a rare complication of advanced pancreatic cancer,…